- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Dr. Reddy's in the news
-
Heart drugs in demand
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Lab Launches shot in US
Click Here for the Complete Story [PDF Format] -
Dr Reddy's launches generic Methylprednisolone Sodium Succinate for injection in US
Click Here for the Complete Story [PDF Format] -
KRChoksey bets on these 6 stocks with an upside of up to 45%
Click Here for the Complete Story [PDF Format] -
Dr Reddy's buys Novartis cardiovascular brand Cidmus in India for Rs 456 crore
Click Here for the Complete Story [PDF Format] -
Dr Reddy inks $61-mn deal to acquire Cidmus brand in India from Novartis
Click Here for the Complete Story [PDF Format] -
Dr.Reddy’s acquiringNovartis cardio drugCidmus for $61 m
Click Here for the Complete Story [PDF Format] -
DRL to buy Novartis cardio drug for $61m
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's announces introduction of medical cannabis products in Germany
Click Here for the Complete Story [PDF Format] -
Dr Reddy’s to buy Novartis’s cardio drug Cidmus for Rs 463 crore
Click Here for the Complete Story [PDF Format] -
Dr Reddy’s expands data science team, appoints new Head of Analytics
Click Here for the Complete Story [PDF Format] -
Dr Reddy’s: Improving exposure to EMs adds to investment case
Click Here for the Complete Story [PDF Format] -
India, UAE trade pact may come into force from May 1: Goyal
Click Here for the Complete Story [PDF Format] -
CEO Spotlight: Akhil Ravi
Click Here for the Complete Story [PDF Format] -
Our People Practices Have Always Been Ahead Of Times," Archana Bhaskar
Click Here for the Complete Story [PDF Format] -
Delhi High Court imposes ₹1 lakh costs on 2 registrars from Trade Marks Controller General's office for concealing facts
Click Here for the Complete Story [PDF Format] -
Were exploring AL, ML techniques for molecular design & various prediction of drug candidates
Click Here for the Complete Story [PDF Format] -
Board of Dr Reddys Laboratories appoints company secretary and compliance officer
Click Here for the Complete Story [PDF Format] -
Buy Dr. Reddy's Laboratories, target price Rs 5385: Emkay Global
Click Here for the Complete Story [PDF Format] -
India CEOs On Automated Plants, New Modalities, Tackling 'The Great Talent Reshuffle'
Click Here for the Complete Story [PDF Format] -
4 pharma and metal stocks to buy in this market: Rahul Shah
Click Here for the Complete Story [PDF Format] -
Record number of jobseekers at Cambridge Network careers fair
Click Here for the Complete Story [PDF Format] -
Valuations turning attractive for Dr Reddys as company outperforms sector
Click Here for the Complete Story [PDF Format] -
Expand PLI scheme for pharma to make it research-linked, says industry
Click Here for the Complete Story [PDF Format] -
Here are the top 20 BSE 100 companies with strong corporate governance: Report
Click Here for the Complete Story [PDF Format] -
Pharma industry likely to grow to $130 billion by 2030: Industry leaders
Click Here for the Complete Story [PDF Format] -
Dr Reddy’s Chairman Satish Reddy seeks govt-industry joint fund for R&D
Click Here for the Complete Story [PDF Format] -
Time for Indian pharma to raise the game
Click Here for the Complete Story [PDF Format] -
Risk-reward ratio is favourable in select pharma companies: CLSA
Click Here for the Complete Story [PDF Format] -
Binnopharm Group to acquire Dr.Reddy’s two antibacterial brands inRussia,CIS region
Click Here for the Complete Story [PDF Format] -
Binnopharm to acquire anti-bacterial brands from Dr Reddy’s in Russia, CIS region
Click Here for the Complete Story [PDF Format] -
Dr Reddy's divests two antibiotic brands Ciprolet and Levolet in Russia & CIS countries
Click Here for the Complete Story [PDF Format] -
Dr Reddys Gets USFDA EIR For Duvvada Facilities
Click Here for the Complete Story [PDF Format] -
Mankind Pharma to acquire Combihale and Daffy brands from Dr Reddy's Laboratories
Click Here for the Complete Story [PDF Format] -
Dr Reddy’s Brings In Range Of Mature Novartis Brands In India
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Lab launches generic version of Vasostrict vials in US market
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's announces the launch of Vasopressin inj (generic version of VASOSTRICT) in the U.S. Market
Click Here for the Complete Story [PDF Format] -
IGBA Launches Panel of 13 CEO-Level Advisers
Click Here for the Complete Story [PDF Format] -
India approves Sputnik Light COVID shot for unvaccinated - local manufacturer
Click Here for the Complete Story [PDF Format] -
DRL unveils Vasotrict generic in U.S.
Click Here for the Complete Story [PDF Format] -
Sputnik Light nod set to boost vaccine's demand
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Laboratories inks exclusive sales pact with Novartis India
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Labs enters into exclusive sales and distribution agreement with Novartis India
Click Here for the Complete Story [PDF Format] -
DRL inks sales pact with Novartis for select brands
Click Here for the Complete Story [PDF Format] -
Dr Reddy's inks exclusive sales pact with Novartis India
Click Here for the Complete Story [PDF Format] -
DCGI grants emergency authorisation for single-dose COVID-19 vaccine Sputnik Light
Click Here for the Complete Story [PDF Format] -
Dr Reddys In S&P Global Sustainability Yearbook For 2nd
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's Laboratories announces DCGI approval to the single-shot Sputnik Light vaccine in India
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Laboratories inks agreement to acquire Nimbus Health GmbH
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to buy German pharma firm Nimpus Health
Click Here for the Complete Story [PDF Format] -
DRL to acquire German medical cannabis player Nimbus Health
Click Here for the Complete Story [PDF Format] -
Covid: India grants restricted emergency use to single-dose Sputnik Light vaccine
Click Here for the Complete Story [PDF Format] -
Sputnik Light is second vaccine to be made available in India by Dr. Reddy’s
Click Here for the Complete Story [PDF Format] -
Dr Reddy's gets DCGI nod for single-shot Sputnik Light vaccine
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's Gets DCGI Nod For Single-Shot Sputnik Light Vaccine In India
Click Here for the Complete Story [PDF Format] -
Medicinal cannabis: What it is, its legal status in India and everything you need to know
Click Here for the Complete Story [PDF Format] -
Dr Reddy's: Supported by traction in limited competition products
Click Here for the Complete Story [PDF Format] -
Dr Reddy's in Gender Equality Index 2022
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's in S&P Global's Sustainability Yearbook for 2nd year
Click Here for the Complete Story [PDF Format] -
'Make in India' to 'Discover and Make in India'
Click Here for the Complete Story [PDF Format] -
No Booster Dose For Biotech In Budget' 22
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Lab Q3 results: Net profit soars over 25 times to Rs 707 cr
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's Q3 Results: Profit Surges On Higher Sales In Key Markets
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to enter medical cannabis business, to buy German firm Nimbus
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Q3 net profit rises multi-fold to Rs 707 cr
Click Here for the Complete Story [PDF Format] -
Dr Reddys Ropes In Penny Wan As Additional Director
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's Labs Rating 'Hold'; A steady Q3FY22 for the pharma company
Click Here for the Complete Story [PDF Format] -
DRL Q3 Results: Drugmaker posts 25 times rise in PAT at Rs 709 cr, in line with estimates
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's bags Sustainability 4.0 Awards
Click Here for the Complete Story [PDF Format] -
Fermenta Biotech licenses its proprietaryenzymatic technology for manufacturingMolnupiravir to Aurigene Pharma
Click Here for the Complete Story [PDF Format] -
Fermenta Biotech Limited exclusively licenses its proprietary enzymatic technology for manufacturing Molnupiravir to Aurigene Pharmaceutical Services Ltd
Click Here for the Complete Story [PDF Format] -
Fermenta has signed a Definitive Agreement with Aurigene for Molnupiravir
Click Here for the Complete Story [PDF Format] -
Fermenta has signed a Definitive Agreement with Aurigene, a stepdown subsidiary of Dr. Reddy's Limited
Click Here for the Complete Story [PDF Format] -
Innovation in R&D Top Focus
Click Here for the Complete Story [PDF Format] -
Dr Reddy's Labs bags Frost & Sullivan and TERI’s Sustainability 4.0 Awards 2021
Click Here for the Complete Story [PDF Format] -
Budget 2022-23 Wishlist
Click Here for the Complete Story [PDF Format] -
India to become hub for Covid-19 antiviral generic drugs: Fitch
Click Here for the Complete Story [PDF Format] -
Raising their generics game
Click Here for the Complete Story [PDF Format] -
University of Hyderabad, Dr Reddy's to build cold chain solutions for pharma industry
Click Here for the Complete Story [PDF Format] -
Merck's Anti - Covid Pill 'Molflu' 5-Day Course To Cost ₹1,400 In India
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment
Click Here for the Complete Story [PDF Format] -
Dr Reddy's to launch molnupiravir next week at ₹35 per capsule
Click Here for the Complete Story [PDF Format] -
India Inc sees investment boom, lines up capex plans
Click Here for the Complete Story [PDF Format] -
Predictions 2022
Click Here for the Complete Story [PDF Format]
